Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
532
Completed, industry sponsors, Psychiatry, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed532
532 trials
Showing 1 to 25, recently updated first.
Transcend TherapeuticsIndustry
NCT06237426 · 44 participants · Start Mar 6, 2024 · Primary completion Oct 6, 2025
Drug: Methylone · For: Post Traumatic Stress Disorder
Sites: Denver, Colorado; Rockville, Maryland; Draper, Utah · 9 sites in all
- Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With SchizophreniaPivotal-lookingCompleted
Celon Pharma SAIndustry
NCT05278156 · 189 participants · Start May 19, 2021 · Primary completion Jun 5, 2024
Drug: CPL500036 - low dose; CPL500036 - high dose and 1 more · For: Schizophrenia
Sites: Budapest, Hungary; Győr, Hungary; Kalocsa, Hungary · 16 sites in all
Initiator PharmaIndustry
NCT04686916 · 24 participants · Start Dec 30, 2020 · Primary completion Jul 30, 2023
Drug: IP2018; Placebo · For: Erectile Dysfunction
Sites: Manchester, United Kingdom
VistaGen Therapeutics, Inc.Industry
NCT06809179 · 61 participants · Start Jan 9, 2025 · Primary completion Jun 12, 2026
Drug: Fasedienol Nasal Spray - Placebo Nasal Spray; Fasedienol Nasal Spray - Fasedienol Nasal Spray and 1 more · For: Social Anxiety Disorder
Sites: Sherman Oaks, California; Walnut Creek, California; Largo, Florida · 9 sites in all
- BTRX-246040 Administered Once Daily to Patients With Major Depressive DisorderPivotal-lookingCompleted
BlackThorn Therapeutics, Inc.Industry
NCT03193398 · 104 participants · Start Jun 12, 2017 · Primary completion Nov 12, 2018
Drug: BTRX-246040 oral capsule(s); Placebo oral capsule(s) · For: Major Depressive Disorder
Sites: Cerritos, California; Garden Grove, California; Jacksonville, Florida · 8 sites in all
- A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)Pivotal-lookingCompleted
atai Therapeutics, Inc.Industry
NCT06524830 · 142 participants · Start Dec 30, 2024 · Primary completion Jul 30, 2026
Drug: VLS-01-203 BU; VLS-01-BU Placebo · For: Treatment Resistant Depression
Sites: Tucson, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 48 sites in all
Transcend TherapeuticsIndustry
NCT06215261 · 62 participants · Start Apr 4, 2024 · Primary completion Sep 23, 2025
Drug: Methylone · For: Post Traumatic Stress Disorder
Sites: Lauderhill, Florida; Maitland, Florida; Orlando, Florida · 12 sites in all
- A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaPivotal-lookingCompleted
Kynexis B.V.Industry
NCT07191483 · 149 participants · Start Aug 27, 2025 · Primary completion Sep 9, 2026
Drug: KYN-5356 low dose; KYN-5356 Medium Dose and 1 more · For: Cognitive Impairment Associated With Schizophrenia (CIAS)
Sites: Little Rock, Arkansas; Cerritos, California; Lemon Grove, California · 15 sites in all
- Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02153502 · 206 participants · Start Jul 1, 2014 · Primary completion Feb 1, 2016
Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination); Placebo · For: Depressive Disorder, Treatment-Resistant
Sites: Birmingham, Alabama; Bellflower, California; Costa Mesa, California · 32 sites in all
- A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDDPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT06236880 · 126 participants · Start Jan 31, 2024 · Primary completion Jul 27, 2026
Drug: GM-2505 · For: Major Depressive Disorder
Sites: Manchester, United Kingdom
- Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT06605599 · 161 participants · Start Oct 15, 2024 · Primary completion Nov 12, 2025
Drug: ABBV-932; Placebo for ABBV-932 · For: Bipolar I Disorder; Bipolar II Disorder
Sites: Dothan, Alabama; Anaheim, California; Colton, California · 40 sites in all
- Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionPivotal-lookingCompleted
Biohaven Therapeutics Ltd.Industry
NCT06419608 · 336 participants · Start May 28, 2024 · Primary completion Nov 7, 2025
Drug: BHV-7000; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 62 sites in all
Biohaven Therapeutics Ltd.Industry
NCT06423781 · 233 participants · Start Aug 1, 2024 · Primary completion Mar 18, 2026
Drug: BHV-7000 · For: Major Depressive Disorder
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 66 sites in all
BioXcel Therapeutics IncIndustry
NCT07116694 · 33 participants · Start Jun 19, 2025 · Primary completion Oct 7, 2025
Drug: BXCL501 Sublingual Film · For: Bipolar I Disorder; Bipolar II Disorder; Schizophrenia and 3 more
Sites: Chino, California; Oceanside, California; Orange, California · 5 sites in all
- A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06785012 · 105 participants · Start Dec 26, 2024 · Primary completion Jun 25, 2026
Drug: JNJ-89495120; Placebo · For: Depressive Disorder, Major
Sites: Huntsville, Alabama; Chandler, Arizona; Phoenix, Arizona · 44 sites in all
- A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.Pivotal-lookingCompleted
EMSIndustry
NCT07843056 · 121 participants · Start May 10, 2022 · Primary completion Jan 20, 2026
Drug: WAS123; Aripiprazole (Fixed dose) · For: Schizophenia Disorder
Sites: São Paulo, Brazil
- A Phase II Study to Evaluate NH102 for DepressionPivotal-lookingCompleted
Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
NCT06842992 · 243 participants · Start Dec 4, 2024 · Primary completion Jul 30, 2025
Drug: NH102; NH102 and 3 more · For: Major Depressive Disorder (MDD)
Sites: Hefei, China; Beijing, China; Chongqing, China · 24 sites in all
- A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderPivotal-lookingCompleted
Xenon Pharmaceuticals Inc.Industry
NCT05376150 · 168 participants · Start May 19, 2022 · Primary completion Sep 18, 2023
Drug: XEN1101 10 mg; XEN1101 20 mg and 1 more · For: Major Depressive Disorder
Sites: Anaheim, California; Lafayette, California; Pico Rivera, California · 20 sites in all
- ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety DisorderPivotal-lookingCompleted
Engrail Therapeutics INCIndustry
NCT05749055 · 252 participants · Start Jul 3, 2023 · Primary completion Sep 18, 2025
Drug: ENX-102; Placebo · For: Generalized Anxiety Disorder
Sites: Phoenix, Arizona; Garden Grove, California; Imperial, California · 32 sites in all
- A Comparator Study of LY2140023 Versus Placebo in Schizophrenia PatientsPivotal-lookingCompleted
Denovo Biopharma LLCIndustry
NCT01086748 · 1,134 participants · Start Mar 2010 · Primary completion May 2012
Drug: Risperidone; Placebo and 1 more · For: Schizophrenia
Sites: Escondido, California; Garden Grove, California; Paramount, California · 28 sites in all
- A Study for Participants With SchizophreniaPivotal-lookingCompleted
Denovo Biopharma LLCIndustry
NCT00520923 · 669 participants · Start Sep 2007 · Primary completion Oct 2008
Drug: LY2140023; Olanzapine and 1 more · For: Schizophrenia
Sites: Banfield, Argentina; Buenos Aires, Argentina; Lanus, Argentina · 35 sites in all
- BPL-003 Efficacy and Safety in Treatment Resistant DepressionPivotal-lookingCompleted
Beckley Psytech LimitedIndustry
NCT05870540 · 196 participants · Start Sep 14, 2023 · Primary completion Mar 28, 2025
Drug: BPL-003; BPL-003 · For: Treatment Resistant Depression
Sites: Birmingham, Alabama; Rogers, Arkansas; San Diego, California · 42 sites in all
Sichuan Purity Pharmaceutical Technology Co., Ltd.Industry
NCT07193901 · 98 participants · Start May 27, 2025 · Primary completion Apr 10, 2026
Drug: Low Dose PRT042 nasal spray; median Dose PRT042 nasal spray and 2 more · For: Major Depressive Disorder (MDD
Sites: Beijin, China; Beijing, China; Changsha, China · 15 sites in all
Suven Life Sciences LimitedIndustry
NCT06126497 · 41 participants · Start Feb 5, 2024 · Primary completion Jul 19, 2024
Drug: Ropanicant · For: Major Depressive Disorder
Sites: Bellflower, California; Orange, California; Torrance, California · 10 sites in all
- Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive DisorderPivotal-lookingCompleted
Hangzhou PhecdaMed Co., Ltd.Industry
NCT07018245 · 149 participants · Start Jul 9, 2025 · Primary completion Jun 25, 2026
Drug: TJ0113; Placebo · For: Depression
Sites: Hangzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.